enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update
by Teresa Graham · The Cerbat GemenGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,145,907 shares, an increase of 24.2% from the March 15th total of 922,661 shares. Currently, 1.9% of the shares of the company are sold short. Based on an average daily volume of 279,661 shares, the days-to-cover ratio is presently 4.1 days.
Hedge Funds Weigh In On enGene
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PFS Partners LLC grew its stake in enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after buying an additional 2,000 shares during the last quarter. Millennium Management LLC raised its stake in shares of enGene by 57.3% in the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after acquiring an additional 7,472 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares in the last quarter. Cresset Asset Management LLC acquired a new position in shares of enGene in the 2nd quarter worth approximately $36,000. Finally, Paloma Partners Management Co bought a new stake in enGene during the 2nd quarter worth approximately $38,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
ENGN has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a report on Wednesday, April 8th. Jefferies Financial Group initiated coverage on shares of enGene in a report on Friday, January 30th. They set a “buy” rating and a $28.00 price objective for the company. Raymond James Financial reiterated a “strong-buy” rating and set a $27.00 target price on shares of enGene in a research report on Monday, March 9th. Citigroup reissued a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. Finally, Wall Street Zen lowered shares of enGene from a “hold” rating to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $22.69.
Get Our Latest Stock Analysis on enGene
enGene Stock Performance
enGene stock opened at $8.07 on Friday. The firm has a market capitalization of $540.61 million, a P/E ratio of -3.59 and a beta of -0.06. The stock has a fifty day moving average price of $8.21 and a two-hundred day moving average price of $8.36. enGene has a 52-week low of $2.65 and a 52-week high of $12.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 11.75.
enGene (NASDAQ:ENGN – Get Free Report) last issued its earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.11. As a group, analysts anticipate that enGene will post -1.56 EPS for the current fiscal year.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.